CA2674803C
(en)
*
|
1999-02-10 |
2012-10-09 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors
|
ATE330954T1
(de)
|
1999-11-05 |
2006-07-15 |
Astrazeneca Ab |
Quinazolin-derivate als vegf-hemmer
|
AU2001235804A1
(en)
*
|
2000-03-06 |
2001-09-17 |
Astrazeneca Ab |
Therapy
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
US7115615B2
(en)
*
|
2000-08-21 |
2006-10-03 |
Astrazeneca |
Quinazoline derivatives
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2001292138A1
(en)
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
MX242553B
(es)
|
2000-10-20 |
2006-12-06 |
Eisai Co Ltd |
Derivados aromaticos que contienen nitrogeno.
|
AU2002217999A1
(en)
|
2000-11-01 |
2002-05-15 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
SI2311825T1
(sl)
|
2000-12-21 |
2016-02-29 |
Novartis Ag |
Pirimidinamini kot angiogenetski modulatorji
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7105682B2
(en)
*
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6995162B2
(en)
*
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
PE20021011A1
(es)
*
|
2001-03-23 |
2003-02-01 |
Bayer Corp |
Derivados quinazolinicos como inhibidores de la rho-quinasa
|
JP4320705B2
(ja)
*
|
2001-03-23 |
2009-08-26 |
バイエル コーポレイション |
Rhoキナーゼ阻害剤
|
WO2002085895A1
(en)
*
|
2001-04-19 |
2002-10-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
EP1409481B1
(de)
*
|
2001-07-16 |
2006-10-04 |
Astrazeneca AB |
Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
|
GB0128109D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
EP1474420B1
(de)
*
|
2002-02-01 |
2012-03-14 |
AstraZeneca AB |
Chinazoline verbindungen
|
ATE533750T1
(de)
|
2002-02-06 |
2011-12-15 |
Ube Industries |
Verfahren zur herstellung einer 4- aminochinazolinverbindung
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
AU2003281193A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
JP4703183B2
(ja)
|
2002-07-15 |
2011-06-15 |
シンフォニー エボルーション, インク. |
受容体型キナーゼモジュレーターおよびその使用方法
|
CN1688549A
(zh)
*
|
2002-08-23 |
2005-10-26 |
麒麟麦酒株式会社 |
具有TGFβ抑制活性的化合物和含所述化合物的药用组合物
|
CA2503371C
(en)
|
2002-11-04 |
2011-01-11 |
Astrazeneca Ab |
Quinazoline derivatives as src tyrosine kinase inhibitors
|
ATE508747T1
(de)
|
2003-03-10 |
2011-05-15 |
Eisai R&D Man Co Ltd |
C-kit kinase-hemmer
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0310401D0
(en)
*
|
2003-05-07 |
2003-06-11 |
Astrazeneca Ab |
Therapeutic agent
|
GB0316127D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0316123D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0318422D0
(en)
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
CN103772373B
(zh)
*
|
2003-08-14 |
2017-06-09 |
阿雷生物药品公司 |
作为受体酪氨酸激酶抑制剂的喹唑啉类似物
|
AU2004275842B2
(en)
|
2003-09-26 |
2010-09-02 |
Exelixis Inc. |
c-MET modulators and methods of use
|
JP4303726B2
(ja)
|
2003-11-11 |
2009-07-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウレア誘導体およびその製造方法
|
GB0328040D0
(en)
*
|
2003-12-03 |
2004-01-07 |
Coleman Robert E |
Pharmaceutical uses of bisphosphonates
|
JP4503022B2
(ja)
|
2003-12-23 |
2010-07-14 |
ファイザー・インク |
新規キノリン誘導体
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2005206571B8
(en)
*
|
2004-01-23 |
2010-09-02 |
Amgen Inc. |
Compounds and methods of use
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
GB0406445D0
(en)
*
|
2004-03-23 |
2004-04-28 |
Astrazeneca Ab |
Combination therapy
|
EP1740170A2
(de)
*
|
2004-03-23 |
2007-01-10 |
AstraZeneca AB |
Kombinationstherapie mit einem antitumoralen mittel aus azd2171 und platin
|
GB0406446D0
(en)
*
|
2004-03-23 |
2004-04-28 |
Astrazeneca Ab |
Combination therapy
|
US7880000B2
(en)
|
2004-05-07 |
2011-02-01 |
Amgen Inc. |
Protein kinase modulators and method of use
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
EP1797877A4
(de)
|
2004-09-13 |
2010-12-15 |
Eisai Co Ltd |
Gemeinsame verwendung einer verbindung auf sulfonamid-basis mit einem angiogenese-hemmer
|
CN101001629B
(zh)
|
2004-09-17 |
2010-05-05 |
卫材R&D管理有限公司 |
药物组合物
|
AR050948A1
(es)
|
2004-09-24 |
2006-12-06 |
Hoffmann La Roche |
Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
AU2005288736B2
(en)
*
|
2004-09-27 |
2008-08-14 |
Astrazeneca Ab |
Cancer combination therapy comprising AZD2171 and imatinib
|
ES2378772T3
(es)
|
2004-10-12 |
2012-04-17 |
Astrazeneca Ab |
Derivados de quinazolina
|
AU2005312048B2
(en)
|
2004-11-30 |
2012-08-02 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
RU2394839C2
(ru)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Антитела против ангиопоэтина-2 и их применение
|
EP1674467A1
(de)
*
|
2004-12-22 |
2006-06-28 |
4Sc Ag |
2,5- und 2,6-disubstituierte Benzazol-Derivate zur Verwendung als Protein Kinase Inhibitoren
|
AU2006233537A1
(en)
|
2005-04-14 |
2006-10-19 |
F. Hoffmann-La Roche Ag |
Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
EP2361905B1
(de)
|
2005-05-18 |
2013-03-06 |
Array Biopharma Inc. |
Heterocyclische MEK Inhibitoren und ihre Verwendung
|
EP1896461A2
(de)
|
2005-06-30 |
2008-03-12 |
Amgen Inc. |
Bis-aryl kinase inhibitoren für die behandlung von entzündungen, angiogenese und krebs
|
EP1925941B1
(de)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
WO2007026864A1
(ja)
*
|
2005-09-01 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
崩壊性の改善された医薬組成物の製造方法
|
US8247556B2
(en)
|
2005-10-21 |
2012-08-21 |
Amgen Inc. |
Method for preparing 6-substituted-7-aza-indoles
|
EP1949902B1
(de)
*
|
2005-11-07 |
2012-06-27 |
Eisai R&D Management Co., Ltd. |
Verwendung einer kombination einer anti-angiogenen substanz und c-kit-kinase-hemmer
|
WO2007061127A1
(ja)
*
|
2005-11-22 |
2007-05-31 |
Eisai R & D Management Co., Ltd. |
多発性骨髄腫に対する抗腫瘍剤
|
GB0523810D0
(en)
*
|
2005-11-23 |
2006-01-04 |
Astrazeneca Ab |
Pharmaceutical compositions
|
CA2631676A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Astrazeneca Ab |
Combination of azd2171 and pemetrexed
|
US7868177B2
(en)
|
2006-02-24 |
2011-01-11 |
Amgen Inc. |
Multi-cyclic compounds and method of use
|
JP2009528365A
(ja)
*
|
2006-02-28 |
2009-08-06 |
アムゲン インコーポレイティッド |
ホスホジエステラーゼ10阻害剤としてのシンノリン及びキナゾリン誘導体
|
UY30183A1
(es)
*
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
EP1994024A2
(de)
*
|
2006-03-02 |
2008-11-26 |
AstraZeneca AB |
Chinolinderivate
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
WO2007136103A1
(ja)
*
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
EP2044939A1
(de)
*
|
2006-06-29 |
2009-04-08 |
Eisai R&D Management Co., Ltd. |
Therapeutisches mittel gegen leberfibrose
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DK2057156T3
(en)
|
2006-08-23 |
2017-05-08 |
Kudos Pharm Ltd |
2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
|
EP2065372B1
(de)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumormittel gegen undifferenzierten magenkrebs
|
WO2008033748A2
(en)
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Quinazoline based egfr inhibitors containing a zinc binding moiety
|
AU2012204077B2
(en)
*
|
2006-11-02 |
2012-11-29 |
Astrazeneca Ab |
Process for preparing indol-5-oxy-quinazoline derivatives and intermediates
|
CL2007003158A1
(es)
*
|
2006-11-02 |
2008-05-16 |
Astrazeneca Ab |
Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
ES2387471T3
(es)
|
2006-12-20 |
2012-09-24 |
Amgen Inc. |
Compuestos heterocíclicos y su uso en el tratamiento de la inflamación, la angiogénesis y el cáncer
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
JP5377332B2
(ja)
|
2007-02-06 |
2013-12-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
US8148532B2
(en)
|
2007-03-14 |
2012-04-03 |
Guoqing Paul Chen |
Spiro substituted compounds as angiogenesis inhibitors
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
PE20081887A1
(es)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
US20100130519A1
(en)
*
|
2007-04-13 |
2010-05-27 |
Stephen Robert Wedge |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
CA2684470C
(en)
|
2007-04-16 |
2016-02-09 |
Hutchison Medipharma Enterprises Limited |
Pyrimidine derivatives
|
WO2009030224A2
(de)
*
|
2007-09-07 |
2009-03-12 |
Schebo Biotech Ag |
Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
|
TW200922590A
(en)
*
|
2007-09-10 |
2009-06-01 |
Curis Inc |
VEGFR inhibitors containing a zinc binding moiety
|
CA2698944C
(en)
|
2007-09-10 |
2015-06-16 |
Curis, Inc. |
Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
|
US8119616B2
(en)
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
CA2703257C
(en)
*
|
2007-10-29 |
2013-02-19 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
EP2218712B1
(de)
|
2007-11-09 |
2015-07-01 |
Eisai R&D Management Co., Ltd. |
Kombination einer antiangiogenen substanz und eines platinkomplexes mit antitumorwirkung
|
PL2222675T3
(pl)
|
2007-12-19 |
2014-02-28 |
Genentech Inc |
5-anilinoimidazopirydyny i sposoby zastosowania
|
JP5710269B2
(ja)
|
2007-12-21 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
アザインドリジン類と使用方法
|
CN101215274B
(zh)
*
|
2007-12-27 |
2011-05-04 |
上海北卡医药技术有限公司 |
N取代吗啉类有机化合物的制备工艺
|
WO2009089851A1
(en)
*
|
2008-01-17 |
2009-07-23 |
Bayer Schering Pharma Aktiengesellschaft |
Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
|
WO2009094211A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Quinazoline compounds and methods of treating cancer
|
MX2010008187A
(es)
*
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
MX2010008621A
(es)
|
2008-02-07 |
2010-09-24 |
Boehringer Ingelheim Int |
Heterociclos espirociclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion.
|
US20110028471A1
(en)
*
|
2008-02-21 |
2011-02-03 |
Astrazeneca Ab |
Combination therapy 238
|
CN101980708B
(zh)
*
|
2008-03-26 |
2013-03-13 |
诺瓦提斯公司 |
作为vegf驱动的血管生成过程的有效调节剂的咪唑并喹啉类及嘧啶衍生物
|
US7829574B2
(en)
*
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
CA2723989C
(en)
|
2008-05-13 |
2017-04-25 |
Astrazeneca Ab |
Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
|
US8426430B2
(en)
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
EP2149565A1
(de)
*
|
2008-07-24 |
2010-02-03 |
Bayer Schering Pharma AG |
Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
US8211911B2
(en)
*
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
TW201008933A
(en)
|
2008-08-29 |
2010-03-01 |
Hutchison Medipharma Entpr Ltd |
Pyrimidine compounds
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
US8293897B2
(en)
*
|
2008-10-14 |
2012-10-23 |
Ning Xi |
Compounds comprising a spiro-ring and methods of use
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
EP2379595A2
(de)
|
2008-12-23 |
2011-10-26 |
AstraZeneca AB |
Gegen a5b1 gerichtete gezielt bindende mittel und anwendungen davon
|
KR102187034B1
(ko)
|
2009-01-16 |
2020-12-04 |
엑셀리시스, 인코포레이티드 |
암 치료용 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
|
JP5977522B2
(ja)
|
2009-02-05 |
2016-08-24 |
イミュノジェン・インコーポレーテッド |
新規ベンゾジアゼピン誘導体
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
CN102388048B
(zh)
|
2009-02-10 |
2014-07-30 |
阿斯利康(瑞典)有限公司 |
***并[4,3-b]哒嗪衍生物及其用于***癌的用途
|
US8785457B2
(en)
|
2009-03-13 |
2014-07-22 |
Cellzome Limited |
Pyrimidine derivatives as mTOR inhibitors
|
IT1393351B1
(it)
*
|
2009-03-16 |
2012-04-20 |
Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa |
Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
|
AU2010229147B2
(en)
*
|
2009-03-21 |
2012-07-05 |
Sunshine Lake Pharma Co., Ltd. |
Amino ester derivatives, salts thereof and methods of use
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
EP2419423A1
(de)
|
2009-04-14 |
2012-02-22 |
Cellzome Limited |
Fluorsubstituierte pyridinverbindungen als jak3-inhibitoren
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
EP2475648A1
(de)
|
2009-09-11 |
2012-07-18 |
Cellzome Limited |
Orthosubstituierte pyrimdinverbindungen als jak-inhibitoren
|
NZ598907A
(en)
|
2009-10-20 |
2014-03-28 |
Cellzome Ltd |
Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
IN2012DN03391A
(de)
|
2009-11-18 |
2015-10-23 |
Astrazeneca Ab |
|
SI3279215T1
(sl)
|
2009-11-24 |
2020-07-31 |
Medimmune Limited |
Usmerjena vezavna sredstva proti B7-H1
|
EP2507237A1
(de)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Über toll-like-rezeptoren (tlr) agierende imidazochinoline
|
CA2784807C
(en)
*
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
CN103980338B
(zh)
|
2010-01-15 |
2017-04-26 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
CN102812017A
(zh)
|
2010-01-19 |
2012-12-05 |
阿斯利康(瑞典)有限公司 |
吡嗪衍生物
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Cd20 항체 및 이의 용도
|
EP2542536B1
(de)
|
2010-03-04 |
2015-01-21 |
Cellzome Limited |
Morpholinsubstituierte Harnstoff-Derivate als mTOR-Hemmer
|
EP2566867A1
(de)
|
2010-04-30 |
2013-03-13 |
Cellzome Limited |
Pyrazolverbindungen als jak-hemmer
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
RU2560683C2
(ru)
|
2010-06-25 |
2015-08-20 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
WO2012022681A2
(en)
|
2010-08-20 |
2012-02-23 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
|
US9018197B2
(en)
|
2010-08-28 |
2015-04-28 |
Suzhou Neupharma Co. Ltd. |
Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
EP2638018A1
(de)
|
2010-11-09 |
2013-09-18 |
Cellzome Limited |
Pyridinverbindungen und aza-analoga damit als tyk2-inhibitoren
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
US20130267532A1
(en)
|
2010-11-19 |
2013-10-10 |
Shinya Tosaki |
Cyclic amide compounds and their use in the treatment of disease
|
CN103619865B
(zh)
|
2011-02-02 |
2016-10-12 |
苏州润新生物科技有限公司 |
某些化学个体、组合物及方法
|
ES2717657T3
(es)
|
2011-02-15 |
2019-06-24 |
Immunogen Inc |
Métodos para la preparación de conjugados
|
AU2012216893B2
(en)
|
2011-02-17 |
2016-08-11 |
Cancer Therapeutics Crc Pty Limited |
FAK inhibitors
|
WO2012110774A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
EP2694511A1
(de)
|
2011-04-04 |
2014-02-12 |
Cellzome Limited |
Dihydropyrrol-pyrimidin-derivate als mtor-inhibitoren
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
AU2012288626C1
(en)
|
2011-07-27 |
2015-09-17 |
Astrazeneca Ab |
2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer
|
KR20140047092A
(ko)
|
2011-07-28 |
2014-04-21 |
셀좀 리미티드 |
Jak 억제제로서의 헤테로시클릴 피리미딘 유사체
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013032951A1
(en)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9328081B2
(en)
|
2011-09-01 |
2016-05-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2013040515A1
(en)
|
2011-09-14 |
2013-03-21 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP2014531449A
(ja)
|
2011-09-20 |
2014-11-27 |
セルゾーム リミティッド |
キナーゼ阻害剤としてのピラゾロ[4,3―c]ピリジン誘導体
|
EP2757885B1
(de)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Bestimmte chemische stoffe, zusammensetzungen und verfahren
|
CA2849189A1
(en)
|
2011-09-21 |
2013-03-28 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mtor inhibitors
|
EP2760458B1
(de)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prävention und/oder behandlung von krebs und/oder krebsmetastasen
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
MX341577B
(es)
|
2011-10-07 |
2016-08-25 |
Cellzome Ltd |
Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
|
WO2013092854A1
(en)
|
2011-12-23 |
2013-06-27 |
Cellzome Limited |
Pyrimidine-2,4-diamine derivatives as kinase inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US9670180B2
(en)
|
2012-01-25 |
2017-06-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2626066A1
(de)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Kombinationstherapie mit selektiven VEGFR-2-Inhibitoren und MEK-Inhibitoren
|
US9676813B2
(en)
|
2012-04-29 |
2017-06-13 |
Neupharma, Inc. |
Certain steroids and methods for using the same in the treatment of cancer
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
EP3135690A1
(de)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
|
US9238644B2
(en)
|
2012-08-17 |
2016-01-19 |
Cancer Therapeutics Crc Pty Limited |
VEGFR3 inhibitors
|
EP2887965A1
(de)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Zytotoxische benzodiazepin-derivate
|
ES2907763T3
(es)
|
2012-08-31 |
2022-04-26 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CA2890018A1
(en)
|
2012-11-05 |
2014-05-08 |
Nant Holdings Ip, Llc |
Substituted indol-5-ol derivatives and their therapeutical applications
|
EP2916838B1
(de)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Bestimmte chemische stoffe, zusammensetzungen und verfahren
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
EP3998267A1
(de)
|
2013-01-31 |
2022-05-18 |
Bellus Health Cough Inc. |
Imidazopyridinverbindungen und verwendungen davon
|
AU2014216178B2
(en)
|
2013-02-15 |
2018-06-28 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
CA2900680C
(en)
*
|
2013-02-20 |
2021-08-10 |
Kala Pharmaceuticals, Inc. |
Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
JP6423804B2
(ja)
|
2013-02-28 |
2018-11-14 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤を含む複合体
|
JP6494533B2
(ja)
|
2013-02-28 |
2019-04-03 |
イミュノジェン・インコーポレーテッド |
細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
|
PT2970263T
(pt)
|
2013-03-13 |
2018-10-03 |
Abbvie Inc |
Processo para a preparação de um agente indutor de apoptóse
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
WO2014144227A1
(en)
|
2013-03-15 |
2014-09-18 |
Magceutics, Inc. |
Magnesium compositions and uses thereof for cancers
|
WO2014145403A1
(en)
|
2013-03-15 |
2014-09-18 |
Nantbio, Inc. |
Substituted indol-5-ol derivatives and their therapeutic applications
|
CN104334543B
(zh)
|
2013-04-09 |
2017-08-25 |
广州慧柏瑞生物医药科技有限公司 |
抗新生血管的化合物、其中间体及其用途
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
EP2806480B1
(de)
*
|
2013-05-20 |
2017-08-09 |
Nintendo Co., Ltd. |
Batterieaufnahmestruktur und Batterieaufnahmeverfahren
|
CN103275069B
(zh)
*
|
2013-05-22 |
2015-03-11 |
苏州明锐医药科技有限公司 |
西地尼布的制备方法
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
KR102339228B1
(ko)
|
2013-08-23 |
2021-12-13 |
뉴파마, 인크. |
특정 화학 물질, 조성물, 및 방법
|
CN103509005B
(zh)
*
|
2013-09-26 |
2015-04-08 |
苏州海特比奥生物技术有限公司 |
喹唑啉类化合物及其制备方法与应用
|
EP3055298B1
(de)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
|
EP2868702A1
(de)
|
2013-10-29 |
2015-05-06 |
DyStar Colours Distribution GmbH |
Dispersfarbstoffe, Herstellung und Verwendung
|
NZ719185A
(en)
|
2013-11-01 |
2017-11-24 |
Kala Pharmaceuticals Inc |
Crystalline forms of therapeutic compounds and uses thereof
|
CA2928665A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
EP4089076A1
(de)
|
2014-08-28 |
2022-11-16 |
Eisai R&D Management Co., Ltd. |
Hochreines chinolinderivat und verfahren zum herstellen davon
|
CN105461698A
(zh)
*
|
2014-09-12 |
2016-04-06 |
杭州普晒医药科技有限公司 |
西地尼布盐及其晶型、以及其制备方法和药物组合物
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
EP3270694A4
(de)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Bestimmte chemische einheiten, zusammensetzungen und verfahren
|
CA2976325C
(en)
|
2015-02-25 |
2023-07-04 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
KR20180018695A
(ko)
|
2015-06-16 |
2018-02-21 |
가부시키가이샤 프리즘 파마 |
항암제
|
EP3957637B1
(de)
|
2015-08-04 |
2023-06-28 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amin-derivate als therapeutische verbindungen
|
US20190112317A1
(en)
|
2015-10-05 |
2019-04-18 |
The Trustees Of Columbia University In The City Of New York |
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
|
CN109069664B
(zh)
|
2016-01-27 |
2022-05-13 |
苏特罗生物制药公司 |
抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
|
KR20180125456A
(ko)
|
2016-02-15 |
2018-11-23 |
아스트라제네카 에이비이 |
세디라닙의 고정된 간헐적 투약을 포함하는 방법
|
RS63609B1
(sr)
|
2016-04-15 |
2022-10-31 |
Cancer Research Tech Ltd |
Heterociklična jedinjenja kao inhibitori ret kinaze
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
CN109843858B
(zh)
|
2016-08-15 |
2023-05-05 |
润新生物公司 |
某些化学实体、组合物及方法
|
WO2018045379A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10336767B2
(en)
*
|
2016-09-08 |
2019-07-02 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
WO2018048747A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CA3037605A1
(en)
|
2016-09-22 |
2018-03-29 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
JP6755775B2
(ja)
*
|
2016-11-04 |
2020-09-16 |
富士アミドケミカル株式会社 |
4−フルオロイソキノリンの製法
|
EP3544971B1
(de)
|
2016-11-22 |
2022-07-06 |
Dana-Farber Cancer Institute, Inc. |
Hemmer der cyclinabhängigen kinase 12 (cdk12) und verwendung davon
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
ES2906439T3
(es)
|
2016-12-05 |
2022-04-18 |
Apros Therapeutics Inc |
Compuestos de pirimidina que contienen grupos ácidos
|
CN106831729A
(zh)
*
|
2016-12-19 |
2017-06-13 |
浙江工业大学 |
一种西地尼布的纯化方法
|
CA3051604A1
(en)
|
2017-02-01 |
2018-08-09 |
Aucentra Therapeutics Pty Ltd |
Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
WO2018215798A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
WO2019034890A1
(en)
|
2017-08-18 |
2019-02-21 |
Cancer Research Technology Limited |
PYRROLO [2,3-B] PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
|
MX2020002666A
(es)
|
2017-09-18 |
2020-11-06 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
|
CN111465601A
(zh)
*
|
2017-10-20 |
2020-07-28 |
卡拉制药公司 |
Ret9和vegfr2抑制剂
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
CN111757881B
(zh)
|
2018-01-15 |
2024-05-07 |
澳升医药公司 |
作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
KR20200143361A
(ko)
|
2018-02-08 |
2020-12-23 |
뉴파마, 인크. |
특정 화학 물질, 조성물, 및 방법
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
ES2939776T3
(es)
|
2018-04-13 |
2023-04-26 |
Cancer Research Tech Ltd |
Inhibidores de BCL6
|
FR3080620B1
(fr)
*
|
2018-04-27 |
2021-11-12 |
Univ Paris Sud |
Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス, インコーポレイテッド |
Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CN112996784B
(zh)
*
|
2018-09-18 |
2023-05-30 |
北京越之康泰生物医药科技有限公司 |
吲哚衍生物及其在医药上的应用
|
AU2019346550A1
(en)
|
2018-09-25 |
2021-04-22 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
CN111747931A
(zh)
|
2019-03-29 |
2020-10-09 |
深圳福沃药业有限公司 |
用于治疗癌症的氮杂芳环酰胺衍生物
|
WO2020201773A1
(en)
|
2019-04-05 |
2020-10-08 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Fgfr阻害剤とするピラゾール類誘導体及びその調製方法
|
MX2022003276A
(es)
|
2019-09-20 |
2022-04-11 |
Ideaya Biosciences Inc |
Derivados de indol e indazol sulfonamido sustituidos en la posicion 4 como inhibidores de parg.
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
CN115151540A
(zh)
|
2019-12-02 |
2022-10-04 |
风暴治疗有限公司 |
作为mettl3抑制剂的多杂环化合物
|
WO2021178597A1
(en)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
CN117396463A
(zh)
|
2021-05-17 |
2024-01-12 |
怡诺安有限公司 |
用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
AU2022359801A1
(en)
|
2021-10-04 |
2024-02-01 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023161881A1
(en)
*
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024003241A1
(en)
|
2022-06-30 |
2024-01-04 |
Astrazeneca Ab |
Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024059169A1
(en)
*
|
2022-09-14 |
2024-03-21 |
Blueprint Medicines Corporation |
Egfr inhibitors
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|